Related Experiment Video
Updated: May 9, 2026

Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
Platelet antiaggregants in stroke prevention
Sarkis G Morales Vidal1, Sean Ruland
1Neurology Department, Stritch School of Medicine, Loyola University Chicago, 2160 South 1st Avenue, Building 105, Room 2700, Maywood, IL 60153, USA. smoralesvidal@lumc.edu
Insights
Antiplatelet agents help prevent recurrent ischemic strokes. This review updates evidence on their optimal use, including timing, dosage, and combinations, for stroke risk reduction and managing side effects.
Area of Science:
- Neurology
- Cardiology
- Pharmacology
Background:
- Antiplatelet therapy is crucial for preventing recurrent ischemic strokes.
- The efficacy and safety of antiplatelet agents depend on various factors like timing, dosage, and combination therapies.
Purpose of the Study:
- To provide an evidence-based update on the latest advancements in antiplatelet therapy for stroke prevention.
- To analyze the impact of different antiplatelet strategies on stroke risk reduction and adverse events.
Main Methods:
- Systematic review of recent clinical trials and observational studies.
- Analysis of data concerning timing, dosage, and combination of antiplatelet agents.
- Evaluation of reported stroke recurrence rates and bleeding complications.
Main Results:
- Different antiplatelet regimens show varying degrees of effectiveness in reducing stroke recurrence.
- Specific dosages and treatment durations are associated with distinct risk-benefit profiles.
- Combination antiplatelet therapy may offer enhanced protection but increases bleeding risk.
Conclusions:
- Optimizing antiplatelet therapy requires careful consideration of individual patient factors and therapeutic strategies.
- Evidence-based guidelines are essential for guiding the appropriate use of antiplatelet agents in stroke prevention.
- Further research is needed to refine antiplatelet protocols for maximizing efficacy and minimizing adverse effects.
Abstract:
Antiplatelet agents are one of the main interventions for recurrent ischemic stroke prevention. Their time of use, dosage, and combination of therapy have different effects in terms of stroke risk reduction and adverse effects. This review provides an evidence-based update of the latest on antiplatelet therapy for stroke prevention.
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Clot Retraction and Fibrinolysis

